| JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies GAM Sanchez, A Reinhardt, S Ramsey, H Wittkowski, PJ Hashkes, ... The Journal of clinical investigation 128 (7), 3041-3052, 2018 | 474 | 2018 |
| National Institutes of Health perspective on reports of gadolinium deposition in the brain AA Malayeri, KM Brooks, LH Bryant, R Evers, P Kumar, DS Reich, ... Journal of the American College of Radiology 13 (3), 237-241, 2016 | 129 | 2016 |
| Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients H Kim, KM Brooks, CC Tang, P Wakim, M Blake, SR Brooks, ... Clinical Pharmacology & Therapeutics 104 (2), 364-373, 2018 | 118 | 2018 |
| Cytokine-mediated systemic adverse drug reactions in a drug–drug interaction study of dolutegravir with once-weekly isoniazid and rifapentine KM Brooks, JM George, AK Pau, A Rupert, C Mehaffy, P De, KM Dobos, ... Clinical Infectious Diseases 67 (2), 193-201, 2018 | 72* | 2018 |
| Differential influence of the antiretroviral pharmacokinetic enhancers ritonavir and cobicistat on intestinal P-glycoprotein transport and the pharmacokinetic/pharmacodynamic … P Kumar, LA Gordon, KM Brooks, JM George, A Kellogg, M McManus, ... Antimicrobial agents and chemotherapy 61 (11), 10.1128/aac. 01201-17, 2017 | 68* | 2017 |
| Integrase inhibitors: after 10 years of experience, is the best yet to come? KM Brooks, EM Sherman, EF Egelund, A Brotherton, S Durham, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 39 (5 …, 2019 | 66 | 2019 |
| Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease O Zimmerman, B Rösler, CS Zerbe, LB Rosen, AP Hsu, G Uzel, ... Open forum infectious diseases 4 (4), ofx202, 2017 | 58 | 2017 |
| Optimizing pharmacology studies in pregnant and lactating women using lessons from HIV: a consensus statement AC Eke, A Olagunju, J Momper, M Penazzato, EJ Abrams, BM Best, ... Clinical Pharmacology & Therapeutics 110 (1), 36-48, 2021 | 38 | 2021 |
| Tenofovir alafenamide use in pregnant and lactating women living with HIV AC Eke, KM Brooks, RD Gebreyohannes, JS Sheffield, KE Dooley, ... Expert opinion on drug metabolism & toxicology 16 (4), 333-342, 2020 | 38 | 2020 |
| Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following tenofovir alafenamide: the TAF-DBS study J Yager, J Castillo-Mancilla, ME Ibrahim, KM Brooks, C McHugh, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 84 (3), 323-330, 2020 | 37 | 2020 |
| Pharmacologic-based methods of adherence assessment in HIV prevention KM Brooks, PL Anderson Clinical pharmacology and therapeutics 104 (6), 1056, 2018 | 37 | 2018 |
| Drug interactions in HIV treatment: complementary & alternative medicines and over-the-counter products KM Brooks, JM George, P Kumar Expert Review of Clinical Pharmacology 10 (1), 59-79, 2017 | 29 | 2017 |
| Pharmacotherapy challenges of fontan‐associated plastic bronchitis: a rare pediatric disease K Brooks, RL Caruthers, KR Schumacher, KA Stringer Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33 (9 …, 2013 | 29 | 2013 |
| Antiretroviral boosting agent cobicistat increases the pharmacokinetic exposure and anticoagulant effect of dabigatran in HIV-negative healthy volunteers LA Gordon, P Kumar, KM Brooks, A Kellogg, M McManus, RM Alfaro, ... Circulation 134 (23), 1909-1911, 2016 | 25 | 2016 |
| Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer H Giovinazzo, P Kumar, A Sheikh, KM Brooks, M Ivanovic, M Walsh, ... Cancer chemotherapy and pharmacology 77, 565-573, 2016 | 24 | 2016 |
| Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV KM Brooks, JD Momper, M Pinilla, AM Stek, E Barr, A Weinberg, ... Aids 35 (3), 407-417, 2021 | 21 | 2021 |
| Safety, tolerability, and pharmacokinetics of radavirsen (AVI‐7100), an antisense oligonucleotide targeting influenza a M1/M2 translation JH Beigel, J Voell, P Muñoz, P Kumar, KM Brooks, J Zhang, P Iversen, ... British journal of clinical pharmacology 84 (1), 25-34, 2018 | 21 | 2018 |
| Adherence to direct-acting antiviral therapy in people actively using drugs and alcohol: the INCLUD study KM Brooks, JR Castillo-Mancilla, M Morrow, S MaWhinney, SE Rowan, ... Open forum infectious diseases 8 (1), ofaa564, 2021 | 18 | 2021 |
| Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/tenofovir alafenamide vs. emtricitabine/tenofovir disoproxil … JL Yager, KM Brooks, JR Castillo-Mancilla, C Nemkov, M Morrow, ... AIDS 35 (15), 2481-2487, 2021 | 16 | 2021 |
| Bioequivalence of tenofovir and emtricitabine after coencapsulation with the proteus ingestible sensor ME Ibrahim, KM Brooks, JR Castillo-Mancilla, C McHugh, M Morrow, ... AIDS Research and Human Retroviruses 34 (10), 835-837, 2018 | 16 | 2018 |
Peter L. AndersonUniversity of Colorado在 cuanschutz.edu 的电子邮件经过验证
